Genmab — August 2018
-
Jeg faldt over lidt historie om Genmab's næste IND, DuoBody-CD40x4-1BB. 50/50 med Biontech. Genmab siger IND i 2018 og Biontech siger 2019 for first in human. http://www.iact-project.eu/IACT_consortium.htm
-
God morgen

-
God morgen

-
Nordea ryddede da vist lige bud siden

-
Kan ikke umiddelbart finde noget nyt andet end den sædvanlige manipulation, og Nordea fortsætter åbenbart deres nettosalg i aktien..
-
The Multiple Myeloma Drug Pipeline-2018: A Review of Small Molecules and Their Therapeutic Targets.....abstract https://www.ncbi.nlm.nih.gov/pubmed/30001985 og fuld artikel https://sci-hub.mu/10.1016/j.clml.2018.06.015 ...aftenlæsning til mange dage;)
-
Antikörper gegen B-Zellen: Ofatumumab nächster Wirkstoffkandidat https://www.deutschesgesundheitsportal.de/2018/08/03/antikoerper-gegen-b-zellen-ofatumumab-naechster-wirkstoffkandidat/
-
Synes godt nok at Nordea har solgt mange aktier her på det sidste. Håber ikke der er grund til bekymring.
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind